Spots Global Cancer Trial Database for non hodgkin lymphoma
Every month we try and update this database with for non hodgkin lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors | NCT05528055 | Solid Tumor Non Hodgkin Lym... | SCR-6920 capsul... SCR-6920 capsul... SCR-6920 capsul... SCR-6920 capsul... | 18 Years - 75 Years | Jiangsu Simcere Pharmaceutical Co., Ltd. | |
| Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation | NCT03842696 | Hematologic Dis... Acute Leukemia ... Chronic Myeloge... Chronic Myeloge... Chronic Myeloge... Myelodysplastic... Mantle Cell Lym... Follicular Lymp... Diffuse Large B... Non Hodgkin Lym... Graft Vs Host D... Graft-versus-ho... | Vorinostat Blood and Marro... Tacrolimus (or ... Methotrexate Mycophenolate M... Cyclophosphamid... | 3 Years - 39 Years | University of Michigan Rogel Cancer Center | |
| A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) | NCT04809467 | Chronic Lymphoc... Non Hodgkin Lym... | tafasitamab parsaclisib | 18 Years - | Incyte Corporation | |
| A Single-cell Transcriptome Study in Patients With Non-Hodgkin's Lymphoma | NCT04434833 | Non Hodgkin Lym... | 14 Years - | Ruijin Hospital | ||
| Safety and Efficacy Evaluation of Next-generation CD19-UCART | NCT05381181 | Acute Lymphobla... Non Hodgkin Lym... | CD19-UCART | 1 Year - 65 Years | Bioray Laboratories | |
| Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers | NCT05834426 | Lymphoma, B-Cel... Neoplasms Cancer High-grade B-ce... Diffuse Large B... Non Hodgkin Lym... Metabolomics | Plasma metabolo... | 18 Years - | Sociedad de Lucha Contra el Cáncer del Ecuador | |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | NCT03452774 | Cancer, Metasta... Cancer Cancer of Pancr... Cancer of Liver Cancer of Stoma... Cancer Liver Cancer of Rectu... Cancer of Kidne... Cancer of Esoph... Cancer of Cervi... Cancer of Colon Cancer of Laryn... Cancer, Lung Cancer, Breast Cancer, Advance... Cancer Prostate Cancer of Neck Cancer of Skin Neuroendocrine ... Carcinoma Mismatch Repair... BRCA Gene Rearr... Non Hodgkin Lym... Leukemia Non Small Cell ... Cholangiocarcin... Glioblastoma Central Nervous... Melanoma Urothelial Carc... Bladder Cancer Ovarian Cancer Endometrial Can... Testicular Canc... Breast Cancer COVID Myelofibrosis Myeloproliferat... Myeloproliferat... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Myelodysplastic... | Clinical Trial ... | - | Massive Bio, Inc. | |
| Integrated Discovery of New Immuno-Molecular Actionable Biomarkers for Tumors With Immune-suppressed Environment | NCT03706625 | Non Hodgkin Lym... Non Small Cell ... Glioma | 18 Years - | Assistance Publique - Hôpitaux de Paris | ||
| Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | NCT05400122 | Colorectal Canc... Hematologic Mal... Rectum Cancer Acute Myeloid L... Myelodysplastic... Acute Lymphobla... Chronic Myeloid... Chronic Lymphoc... Hodgkin Lymphom... Non Hodgkin Lym... Myeloproliferat... Plasma Cell Mye... | Vactosertib Fludarabine Pho... Cyclophosphamid... IL-2 Natural Killer ... | 18 Years - | Case Comprehensive Cancer Center | |
| Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) | NCT03768505 | Follicular Lymp... Non Hodgkin Lym... Marginal Zone L... | Zandelisib (ME-... | 18 Years - | MEI Pharma, Inc. | |
| Immunogenicity of COVID-19 Vaccination in Autologous HSCT or CAR-T Cells Recipients | NCT05597761 | COVID-19 Non Hodgkin Lym... Hodgkin Lymphom... | 18 Years - | University of Cologne | ||
| A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies | NCT04543305 | Multiple Myelom... Acute Myeloid L... Non Hodgkin Lym... Myelodysplastic... | PRT1419 | 18 Years - | Prelude Therapeutics | |
| Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor | NCT04337606 | Non Hodgkin Lym... | Chidamide Decitabine Camrelizumab | 18 Years - 65 Years | Chinese PLA General Hospital | |
| Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab | NCT00946023 | Lymphoma B-cell Lymphoma Non Hodgkin Lym... Chronic Lymphoc... | Fludarabine Cyclophosphamid... Total body irra... Tacrolimus Mycophenolate M... Rituximab Allogeneic Bone... | 1 Year - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas | NCT05400109 | Non Hodgkin Lym... | UF-KURE19 CAR-T... Fludarabine Cyclophosphamid... | 18 Years - | Case Comprehensive Cancer Center | |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | NCT03212404 | Lung Neoplasms Carcinoma, Non-... Carcinoma, Smal... Malignant Mesot... Head and Neck C... Melanoma Merkel Cell Car... Renal Cell Carc... Urothelial Carc... Classical Hodgk... Cutaneous Squam... Non Hodgkin Lym... Endometrial Can... | CK-301 (cosibel... | 18 Years - | Checkpoint Therapeutics, Inc. | |
| Haplo Peripheral Blood Sct In GVHD Prevention | NCT04473911 | GVHD AML ALL MDS MPN CMML Hodgkin Lymphom... Non Hodgkin Lym... Blood Stem Cell... Graft Vs Host D... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Myeloproliferat... Chronic Myelomo... Chemosensitive ... | FLUDARABINE CYCLOPHOSPHAMID... TBI Melphalan Sirolimus Mycophenolate m... RGI-2001 CYCLOPHOSPHAMID... | 18 Years - 80 Years | Massachusetts General Hospital | |
| Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab | NCT00946023 | Lymphoma B-cell Lymphoma Non Hodgkin Lym... Chronic Lymphoc... | Fludarabine Cyclophosphamid... Total body irra... Tacrolimus Mycophenolate M... Rituximab Allogeneic Bone... | 1 Year - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Study to Evaluate CCS1477 in Haematological Malignancies | NCT04068597 | Haematological ... Acute Myeloid L... Non Hodgkin Lym... Multiple Myelom... Higher-risk Mye... Peripheral T Ce... | CCS1477 Pomalidomide Dexamethasone Azacitidine Venetoclax | 18 Years - | CellCentric Ltd. | |
| Adjuvant I.V. Iron Therapy During Erythropoetin Treatment of Anemic Patients With Lymphoproliferative Disorders. | NCT00145652 | Anemia Multiple Myelom... Non Hodgkin Lym... Chronic Lymphoc... | Neo-Recormon an... | 18 Months - | Sundsvall Hospital | |
| Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma | NCT05021770 | Refractory and ... PCNSL Non Hodgkin Lym... | Orelabrutinib Orelabrutinib Thiotepa | 18 Years - | Sun Yat-sen University | |
| A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies | NCT03913949 | Chronic Lymphoc... Non Hodgkin Lym... | APG-2575 | 18 Years - | Ascentage Pharma Group Inc. | |
| Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis | NCT02593123 | Hodgkin's Lymph... Lymphoid Leukem... Lymphoma Leukemia Myeloma Acute Lymphocyt... Non Hodgkin Lym... Chronic Lymphoc... Multiple Myelom... Chronic Myeloge... Myelodysplastic... Recurrent Acute... Recurrent Hodgk... Recurrent Non-H... Recurrent Plasm... Recurrent Chron... Recurrent Chron... Acute Myelogeno... | mycophenolate m... Sargramostim Filgrastim | 18 Years - 74 Years | Virginia Commonwealth University | |
| Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma | NCT05037669 | Acute Lymphobla... Chronic Lymphoc... Non Hodgkin Lym... | PACE CART19 | 18 Years - | University of Pennsylvania | |
| AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW) | NCT06004011 | Cervical Cancer Kaposi Sarcoma Non Hodgkin Lym... | ARROW strategie... One-time educat... | 15 Years - 39 Years | Implenomics | |
| Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL | NCT04206943 | Acute Lymphobla... Non Hodgkin Lym... | Car-T Cell Ther... | 3 Years - 65 Years | Acibadem University | |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | NCT03212404 | Lung Neoplasms Carcinoma, Non-... Carcinoma, Smal... Malignant Mesot... Head and Neck C... Melanoma Merkel Cell Car... Renal Cell Carc... Urothelial Carc... Classical Hodgk... Cutaneous Squam... Non Hodgkin Lym... Endometrial Can... | CK-301 (cosibel... | 18 Years - | Checkpoint Therapeutics, Inc. | |
| Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma | NCT04775680 | Solid Tumor Non Hodgkin Lym... | ADG106 injectio... PD-1 antibody i... | 18 Years - 75 Years | Adagene Inc | |
| Identification of Occupational Exposures in Acute Hematologic Malignancy | NCT03316209 | Non Hodgkin Lym... Chronic Lymphoc... Multiple Myelom... | 20 Years - 80 Years | Centre Hospitalier Intercommunal Creteil | ||
| Improving Exercise Capacity With a Tailored Physical Activity Intervention | NCT05595577 | Non Hodgkin Lym... Heart; Function... Hodgkin Lymphom... Quality of Life | Exercise with T... Cardiopulmonary... MRI scan Quality of Life... Cognitive and B... Blood draws | 18 Years - 85 Years | Wake Forest University Health Sciences | |
| Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma | NCT03185325 | Non Hodgkin Lym... | bone marrow pun... venous blood sa... | - | Assiut University | |
| Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma | NCT02180711 | Non Hodgkin Lym... | acalabrutinib rituximab (IV) Lenalidomide | 18 Years - | Acerta Pharma BV | |
| A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity | NCT04150913 | Non Hodgkin Lym... Refractory Non-... Relapsed Non Ho... Neurotoxicity Neurotoxicity S... Cytokine Releas... | Anakinra Axicabtagene Ci... | 18 Years - | Massachusetts General Hospital | |
| Immunogenicity of COVID-19 Vaccination in Autologous HSCT or CAR-T Cells Recipients | NCT05597761 | COVID-19 Non Hodgkin Lym... Hodgkin Lymphom... | 18 Years - | University of Cologne | ||
| Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) | NCT04240808 | Non Hodgkin Lym... | UCD19 CAR T Cel... | 18 Years - 80 Years | University of Colorado, Denver | |
| Open-Label, Non Randomized Phase 2 Study With Safety Run-In | NCT02249429 | Lymphoma, Malig... | bimiralisib | 18 Years - | PIQUR Therapeutics AG | |
| Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma | NCT03355859 | Non Hodgkin Lym... | JWCAR029 | 18 Years - | Ruijin Hospital | |
| A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) | NCT04809467 | Chronic Lymphoc... Non Hodgkin Lym... | tafasitamab parsaclisib | 18 Years - | Incyte Corporation | |
| CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma | NCT04661020 | Non-hodgkin Lym... | CD19 CAR-T cell... | 18 Years - | Zhejiang University | |
| Cyclophosphamide and Alemtuzumab In Lymphoma | NCT03132584 | Non Hodgkin Lym... High-grade B-ce... Diffuse Large B... | Cyclophosphamid... Alemtuzumab | 18 Years - 75 Years | Dana-Farber Cancer Institute | |
| Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events | NCT05123001 | Hodgkin Lymphom... Non Hodgkin Lym... Leukemia Multiple Myelom... | Biostrap arm ba... | 18 Years - | Stanford University | |
| Haplo Peripheral Blood Sct In GVHD Prevention | NCT04473911 | GVHD AML ALL MDS MPN CMML Hodgkin Lymphom... Non Hodgkin Lym... Blood Stem Cell... Graft Vs Host D... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Myeloproliferat... Chronic Myelomo... Chemosensitive ... | FLUDARABINE CYCLOPHOSPHAMID... TBI Melphalan Sirolimus Mycophenolate m... RGI-2001 CYCLOPHOSPHAMID... | 18 Years - 80 Years | Massachusetts General Hospital | |
| APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) | NCT04419389 | Non Hodgkin Lym... Chronic Lymphoc... Mantle Cell Lym... | APR-246 (eprene... APR-246 (eprene... APR-246 (eprene... APR-246 (eprene... | 18 Years - | Aprea Therapeutics | |
| Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma | NCT03311126 | Mantle Cell Lym... Non-hodgkin Lym... Non Hodgkin Lym... | Bendamustine Obinutuzumab | 18 Years - | University of Wisconsin, Madison | |
| Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma | NCT06180174 | B Cell Lymphoma Non Hodgkin Lym... | MC-1-50 | 18 Years - | Chongqing Precision Biotech Co., Ltd | |
| Integrated Discovery of New Immuno-Molecular Actionable Biomarkers for Tumors With Immune-suppressed Environment | NCT03706625 | Non Hodgkin Lym... Non Small Cell ... Glioma | 18 Years - | Assistance Publique - Hôpitaux de Paris | ||
| Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford | NCT05416554 | Non Hodgkin Lym... | Neuropsychologi... | 18 Years - | Stanford University | |
| Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning | NCT03852407 | Acute Myeloid L... Myelodysplastic... Chronic Myeloid... Myeloproliferat... Myeloproliferat... Acute Lymphoid ... Multiple Myelom... Chronic Lymphoi... Non Hodgkin Lym... Hodgkin Lymphom... | Thymoglobulin Melphalan Fludarabine Cyclophosphamid | 18 Years - 75 Years | University of Liege | |
| Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | NCT02953509 | Non Hodgkin Lym... | Magrolimab Rituximab Gemcitabine Oxaliplatin | 18 Years - | Gilead Sciences | |
| Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma | NCT03688451 | Non Hodgkin Lym... | Rituximab | 18 Years - | University of Cincinnati | |
| Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials | NCT03207256 | Chronic Lymphoc... Non Hodgkin Lym... | TGR-1202 TGR-1202 + Ubli... | - | TG Therapeutics, Inc. | |
| Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | NCT03424603 | B-cell Lymphoma Non Hodgkin Lym... Multiple Myelom... Follicular Lymp... Mantle Cell Lym... Diffuse Large B... Indolent Lympho... B Cells--Tumors | STRO-001 | 18 Years - | Sutro Biopharma, Inc. | |
| Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product | NCT03436771 | Non Hodgkin Lym... Multiple Myelom... Chronic Lymphoc... Diffuse Large B... Mantle Cell Lym... Follicular Lymp... | JCAR017 JCARH125 | - | Juno Therapeutics, a Subsidiary of Celgene | |
| Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events | NCT05123001 | Hodgkin Lymphom... Non Hodgkin Lym... Leukemia Multiple Myelom... | Biostrap arm ba... | 18 Years - | Stanford University | |
| A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma. | NCT06383338 | Hodgkin Lymphom... Non Hodgkin Lym... | Omeprazole Dextromethorpha... | 6 Years - 25 Years | Murdoch Childrens Research Institute | |
| Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma | NCT05420493 | Relapsed Non-Ho... Refractory Non-... Non Hodgkin Lym... | CAR-T cells | 18 Years - | Chongqing Precision Biotech Co., Ltd | |
| Investigating Cognitive Impairment in Young Patients With Cancer Prospectively | NCT05840575 | Chemotherapy-Re... Chemotherapeuti... Chemo-brain Cancer Childhood Cance... Hodgkin Lymphom... Non Hodgkin Lym... Testicular Canc... Sarcoma Leukemia | 7 Years - 29 Years | Rigshospitalet, Denmark | ||
| Improving Communication and Building a Stronger Medical Home Among Spanish-speaking Families | NCT05425992 | Leukemia Non Hodgkin Lym... | Interview | - 22 Years | University of Colorado, Denver | |
| An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma | NCT03779113 | Non Hodgkin Lym... | HMPL-523 | 18 Years - | Hutchmed | |
| Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. | NCT05106192 | Mycosis Fungoid... Cutaneous T-cel... Non Hodgkin Lym... Lymphomatoid Pa... Lymphoma, Large... Lymphoma, Folli... | Med-Jet Injecto... Triamcinolone A... Bexarotene 1% T... Nitrogen Mustar... Conventional sy... | 18 Years - | Case Comprehensive Cancer Center | |
| PRO1160 for Advanced Solid and Liquid Tumors (PRO1160-001) | NCT05721222 | Renal Cell Carc... Nasopharyngeal ... Non Hodgkin Lym... | PRO1160 | 18 Years - | ProfoundBio US Co. | |
| Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | NCT05611853 | B-cell Lymphoma Non Hodgkin Lym... Diffuse Large B... Follicular Lymp... Mantle Cell Lym... | BN301 | 18 Years - | BioNova Pharmaceuticals (Shanghai) LTD. | |
| Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation | NCT03734601 | Acute Myeloid L... Myelodysplastic... Myeloproliferat... Chronic Lymphoc... B-cell Lymphoma T-cell Lymphoma Non Hodgkin Lym... Hodgkin Lymphom... Chronic Myelomo... | Total body irra... Anti-thymocyte ... Tacrolimus Mycophenolate m... Total lymphoid ... | 18 Years - | Stanford University | |
| Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies | NCT03671590 | Non Hodgkin Lym... Chronic Lymphoc... | TG-1701 Umbralisib Ublituximab | 18 Years - | TG Therapeutics, Inc. | |
| Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU | NCT06116110 | Non Hodgkin Lym... | Long-term Follo... | 18 Years - | Miltenyi Biomedicine GmbH | |
| Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | NCT05415098 | Nasopharyngeal ... Castrate Resist... Gastric Cancer Ovarian Clear C... Mesothelioma Sarcoma Non Hodgkin Lym... B Cell Lymphoma Epithelioid Sar... | APG-5918 | 18 Years - | Ascentage Pharma Group Inc. | |
| A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma. | NCT06383338 | Hodgkin Lymphom... Non Hodgkin Lym... | Omeprazole Dextromethorpha... | 6 Years - 25 Years | Murdoch Childrens Research Institute | |
| TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies | NCT06206174 | Hematologic Mal... Non Hodgkin Lym... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... | TGRX-814 | 18 Years - | Shenzhen TargetRx, Inc. | |
| Evaluation of the Analgesy With Emla and/or Nitrous Oxide in Pediatric Patients for Lumbar Puncture | NCT00808171 | Leukemia Non Hodgkin Lym... | Livopan Livopan EMLA | 4 Years - 14 Years | Federal University of Minas Gerais | |
| Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies | NCT04732845 | Non Hodgkin Lym... Acute Lymphobla... Chronic Lymphoc... | Fully human ant... Fludarabine Cyclophosphamid... | 18 Years - | Case Comprehensive Cancer Center | |
| High Dose Therapy and Peripheral Blood Stem Cell Transplantation in HIV Related Non Hodgkin Lymphoma (NHL) at High Risk | NCT01045889 | HIV-related Lym... HIV Infections | Rituximab and C... | 18 Years - 60 Years | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | |
| Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | NCT05400122 | Colorectal Canc... Hematologic Mal... Rectum Cancer Acute Myeloid L... Myelodysplastic... Acute Lymphobla... Chronic Myeloid... Chronic Lymphoc... Hodgkin Lymphom... Non Hodgkin Lym... Myeloproliferat... Plasma Cell Mye... | Vactosertib Fludarabine Pho... Cyclophosphamid... IL-2 Natural Killer ... | 18 Years - | Case Comprehensive Cancer Center | |
| APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) | NCT04419389 | Non Hodgkin Lym... Chronic Lymphoc... Mantle Cell Lym... | APR-246 (eprene... APR-246 (eprene... APR-246 (eprene... APR-246 (eprene... | 18 Years - | Aprea Therapeutics | |
| Improving Communication and Building a Stronger Medical Home Among Spanish-speaking Families | NCT05425992 | Leukemia Non Hodgkin Lym... | Interview | - 22 Years | University of Colorado, Denver | |
| LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies | NCT05990465 | Non Hodgkin Lym... Diffuse Large B... Follicular Lymp... Marginal Zone L... Mantle Cell Lym... Burkitt Lymphom... | Pirtobrutinib LV20.19 CAR T c... | 18 Years - 81 Years | Medical College of Wisconsin | |
| Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma | NCT00907348 | Non Hodgkin Lym... Follicular Lymp... | LR-CHOP21 | 60 Years - 80 Years | Fondazione Italiana Linfomi - ETS | |
| Lymphoma Patients Undergoing Mediastinal Radiotherapy in the Era of Modern Chemoradiation | NCT03969693 | Mediastinal Lym... Hodgkin Lymphom... Non Hodgkin Lym... | Standard treatm... | 15 Years - 80 Years | Chang Gung Memorial Hospital | |
| Antineoplaston Therapy in Treating Patients With Non-Hodgkin's Lymphoma | NCT00003498 | Non Hodgkin Lym... | Antineoplaston ... | 18 Years - 99 Years | Burzynski Research Institute | |
| Copanlisib Pharmacodynamic Study | NCT02155582 | Non Hodgkin Lym... | Copanlisib (BAY... | 18 Years - 100 Years | Bayer | |
| Treosulfan-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies | NCT01079013 | Non Hodgkin Lym... Hodgkin Lymphom... | treosulfan | 18 Years - 68 Years | Sheba Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
